Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.56 |
| ▸ | GAA | P10253 | 2/20 | 0.53 |
| ▸ | MEN1 | O00255 | 2/20 | 0.53 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.53 |
| ▸ | CA1 | P00915 | 5/20 | 0.50 |
| ▸ | CA2 | P00918 | 5/20 | 0.50 |
| ▸ | CA12 | O43570 | 2/20 | 0.50 |
| ▸ | CA9 | Q16790 | 2/20 | 0.50 |
| ▸ | MAOA | P21397 | 1/20 | 0.49 |
| ▸ | MAOB | P27338 | 1/20 | 0.49 |
| ▸ | CTSK | P43235 | 1/20 | 0.46 |
| ▸ | CYP1A2 | P05177 | 3/20 | 0.46 |
| ▸ | TPSAB1 | Q15661 | 1/20 | 0.44 |
| ▸ | TPSD1 | Q9BZJ3 | 1/20 | 0.44 |
| ▸ | TPSG1 | Q9NRR2 | 1/20 | 0.44 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.44 |
| ▸ | CYP2C19 | P33261 | 3/20 | 0.44 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.44 |
| ▸ | TSHR | P16473 | 1/20 | 0.44 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25095054 | 0.95 | TDP1 (0.58) | TDP1GAAMEN1KMT2ACA1 | |
| SCHEMBL7158127 | 0.94 | TDP1 (0.61) | TDP1GAAMEN1KMT2ACA1 | |
| SCHEMBL29256392 | 0.94 | TDP1 (0.61) | TDP1GAAMEN1KMT2ACA1 | |
| SCHEMBL5653695 | 0.94 | TDP1 (0.61) | TDP1GAAMEN1KMT2ACA1 | |
| SCHEMBL13288254 | 0.90 | TDP1 (0.59) | TDP1GAAMEN1KMT2ACA1 | |
| SCHEMBL1784924 | 0.90 | CTSK (0.51) | TDP1GAAMEN1KMT2ACA1 | |
| SCHEMBL25827510 | 0.90 | GAA (0.54) | TDP1GAAMEN1KMT2ACA1 | |
| SCHEMBL20711494 | 0.88 | MAOA (0.56) | TDP1GAAMEN1KMT2ACA1 | |
| SCHEMBL22470268 | 0.88 | TDP1 (0.51) | TDP1GAAMEN1KMT2ACA1 | |
| SCHEMBL27238875 | 0.88 | MEN1 (0.46) | TDP1GAAMEN1KMT2ACA1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 37 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250270197-A1 | RIBOCIL C ANTIBIOTICS EFFECTIVE FOR GRAM-NEGATIVE PATHOGENS | THE BOARD OF TRUSTEES OF THE UNIVERSITY OF ILLINOIS (US) | 2025-08-28 | — | — | US | disclosed |
| US-12180198-B2 | Ribocil C antibiotics effective for Gram-negative pathogens | THE BOARD OF TRUSTEES OF THE UNIVERSITY OF ILLINOIS (US) | 2024-12-31 | — | — | US | disclosed |
| US-20240190872-A1 | FABI INHIBITORS FOR GRAM-NEGATIVE PATHOGENS | THE BOARD OF TRUSTEES OF THE UNIVERSITY OF ILLINOIS (US) | 2024-06-13 | — | — | US | disclosed |
| US-20240116911-A1 | RIBOCIL C ANTIBIOTICS EFFECTIVE FOR GRAM-NEGATIVE PATHOGENS | THE BOARD OF TRUSTEES OF THE UNIVERSITY OF ILLINOIS (US) | 2024-04-11 | — | — | US | disclosed |
| US-11691967-B2 | Antibiotics effective for gram-negative pathogens | THE BOARD OF TRUSTEES OF THE UNIVERSITY OF ILLINOIS (US) | 2023-07-04 | — | — | US | disclosed |
| US-11691967-B2 | Antibiotics effective for gram-negative pathogens | THE BOARD OF TRUSTEES OF THE UNIVERSITY OF ILLINOIS (US) | 2023-07-04 | — | — | US | disclosed |
| US-11691967-B2 | Antibiotics effective for gram-negative pathogens | THE BOARD OF TRUSTEES OF THE UNIVERSITY OF ILLINOIS (US) | 2023-07-04 | — | — | US | disclosed |
| WO-2022187329-A1 | FABI INHIBITORS FOR GRAM-NEGATIVE PATHOGENS | THE BOARD OF TRUSTEES OF THE UNIVERSITY OF ILLINOIS (US) | 2022-09-09 | — | — | WO | disclosed |
| WO-2022187329-A1 | FABI INHIBITORS FOR GRAM-NEGATIVE PATHOGENS | THE BOARD OF TRUSTEES OF THE UNIVERSITY OF ILLINOIS (US) | 2022-09-09 | — | — | WO | disclosed |
| WO-2021249057-A1 | HETEROCYCLIC COMPOUND AND USE THEREOF | 石药集团中奇制药技术（石家庄）有限公司 | 2021-12-16 | — | — | WO | disclosed |
| EP-2601187-A1 | DEUTERATED TANDOSPIRONE DERIVATIVES AS 5-HT1A RECEPTOR AGONISTS | Conrig Pharma ApS (DK) | 2013-06-12 | — | — | EP | disclosed |
| US-8115016-B2 | Process for preparing 5-biphenyl-4-amino-2-methyl pentanoic acid | NOVARTIS AG (CH) | 2012-02-14 | — | — | US | disclosed |
| WO-2012016569-A1 | DEUTERATED TANDOSPIRONE DERIVATIVES AS 5-HT1A RECEPTOR AGONISTS | CONRIG PHARMA APS (DK) | 2012-02-09 | — | — | WO | disclosed |
| WO-2012016569-A1 | DEUTERATED TANDOSPIRONE DERIVATIVES AS 5-HT1A RECEPTOR AGONISTS | CONRIG PHARMA APS (DK) | 2012-02-09 | — | — | WO | disclosed |
| US-20100113801-A1 | Process for preparing 5-biphenyl-4-amino-2-methyl pentanoic acid | NOVARTIS PHARMACEUTICALS CORPORATION | 2010-05-06 | — | — | US | disclosed |
| US-20090215743-A1 | Tricyclic benzazepine derivatives and their use | BAYER HEALTHCARE AG (DE) | 2009-08-27 | — | — | US | disclosed |
| US-20090215743-A1 | Tricyclic benzazepine derivatives and their use | BAYER HEALTHCARE AG (DE) | 2009-08-27 | — | — | US | disclosed |
| US-20090215743-A1 | Tricyclic benzazepine derivatives and their use | BAYER HEALTHCARE AG (DE) | 2009-08-27 | — | — | US | disclosed |
| EP-1706413-A1 | TRICYCLIC BENZAZEPINE DERIVATIVES AS SQUALENE SYNTHASE INHIBITORS USED FOR THE TREATMENT OF CARDIOVASCULAR DISEASES | Bayer HealthCare AG (DE) | 2006-10-04 | — | — | EP | disclosed |
| WO-2005068472-A1 | TRICYCLIC BENZAZEPINE DERIVATIVES AS SQUALENE SYNTHASE INHIBITORS USED FOR THE TREATMENT OF CARDIOVASCULAR DISEASES | BAYER HEALTHCARE AG (DE) | 2005-07-28 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100113801-A1 | Process for preparing 5-biphenyl-4-amino-2-methyl pentanoic acid | MME, REN, PAH | TDP1 2048/4885GAA 1009/4885MEN1 2615/4885 |
| US-11691967-B2 | Antibiotics effective for gram-negative pathogens | PGLS, MGAM, GMDS | TDP1 4238/4885GAA 70/4885MEN1 4333/4885 |
| US-20240116911-A1 | RIBOCIL C ANTIBIOTICS EFFECTIVE FOR GRAM-NEGATIVE PATHOGENS | RPSA, RPS5, RPS2 | TDP1 3533/4885GAA 572/4885MEN1 4532/4885 |
| US-20250270197-A1 | RIBOCIL C ANTIBIOTICS EFFECTIVE FOR GRAM-NEGATIVE PATHOGENS | RPSA, RPS5, RPS2 | TDP1 3533/4885GAA 572/4885MEN1 4532/4885 |
| US-12180198-B2 | Ribocil C antibiotics effective for Gram-negative pathogens | RPSA, RPS5, RPS2 | TDP1 3533/4885GAA 572/4885MEN1 4532/4885 |
| US-20090215743-A1 | Tricyclic benzazepine derivatives and their use | CACNA1I, HDAC3, AADAC | TDP1 1731/4885GAA 851/4885MEN1 3901/4885 |
| US-20240190872-A1 | FABI INHIBITORS FOR GRAM-NEGATIVE PATHOGENS | DBI, MGAM, MGAM2 | TDP1 4652/4885GAA 21/4885MEN1 3974/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.